激励
商业化
孤儿药
药物开发
食品药品监督管理局
业务
药品审批
药品
透视图(图形)
药物发现
药理学
医学
风险分析(工程)
营销
化学
计算机科学
生物信息学
经济
人工智能
微观经济学
生物
生物化学
标识
DOI:10.1021/acs.jmedchem.3c02165
摘要
Expedited development and approval pathways at the Food and Drug Administration (FDA) such as Priority review, Fast Track Designation, Breakthrough Designation, and Accelerated Approval are programs available to drug sponsors that aim to incentivize and expedite the delivery of drugs to patients in need. In addition, other incentive programs such as Orphan Drug Designation (ODD), Qualified Infectious Disease Product Designation (QIDP), and Rare Pediatric Disease Designation (RPDD) are available to drug sponsors to help motivate development of drugs that may have lower economic incentive for commercialization. These programs have been largely effective, and many new innovative drugs since 2010 have accessed these programs. This Perspective highlights how these programs have been used in recent FDA drug approvals and discusses future ways sponsors and regulatory agencies may further enable development of these innovative drugs in the most expeditious fashion.
科研通智能强力驱动
Strongly Powered by AbleSci AI